The Use of a Sequential High Dose Recombinant Interleukin 2 Regimen After Autologous Bone Marrow Transplantation Does Not Improve the Disease Free Survival of Patients with Acute Leukemia Transplanted in First Complete Remission

References

• Zittoun R. A., Mandelli F., Willemze R., De Witte T., Labar B., Resegotti L., Leoni F., Damasio E., Visani G., Papa G., Caronia F., Hayat M., Stryckmans P., Rotoli B., Leoni P., Peetermans M. E., Dardene M., Vegna M. L., Petti M. C., Solbu G., Suciu S. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N. Engl. J. Med. 1995; 332: 217–223
   PubMed Web of Science ®Google Scholar
• Copelan E. A., McGuire E. A. The biology and treatment of acute lymphoblastic leukemia in adults. Blood 1995; 85: 1151–1168
   PubMed Web of Science ®Google Scholar
• Horowitz M. M., Gale R. P., Sondel P. M., Goldman J. M., Kersey J., Kolb H. J., Rimm A. A., Ringden O., Rozman C., Speck B., Truitt R. L., Zwaan F. E., Bortin M. M. Graft‐versus‐leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555–562
   PubMed Web of Science ®Google Scholar
• Maraninchi D., Gluckman E., Blaise D., Guyotat D., Rio B., Pico J. L., Leblond V., Michallet M., Dreyfus F., Lfrah N. Impact of T‐cell depletion on outcome of allogeneic bone marrow transplantation for standard‐risk leukemias. Lancet 1987; 2: 175–178
   PubMed Web of Science ®Google Scholar
• Blaise D., Olive D., Michallet M., Marit G., Leblond V., Maraninchi D. Impairment of leukaemia‐free survival by addition of interleukin‐2 receptor antibody to standard graft‐versus‐host prophylaxis. Lancet 1995; 345: 1144–1146
   PubMed Web of Science ®Google Scholar
• Laporte J. P., Douay L., Lopez M., Labopin M., Jouet J. P., Lesage S., Stachowiak J., Fouillard L., Isnard F., Noel‐Walter M. P., Pene F., Deloux J., Van Den Akker J., Grande M., Bauters F., Najman A., Gorin N. C. One hundred twenty‐five adult patients with primary acute leukemia autografted with marrow purged by mafosfamide: a 10‐year single institution experience. Blood 1994; 84: 3810–3818
   PubMed Web of Science ®Google Scholar
• Reiffers J., Gaspard M. H., Maraninchi D., Michallet M., Marit G., Stoppa A. M., Corront B., David B., Gastaut J. A., Sotto J. J., Broustet A., Carcassonne Y., Hollard D. Comparison of allogeneic or autologous bone marrow transplantation and chemotherapy in patients with acute myeloid leukaemia in first remission: a prospective controlled trial. Br. J. Haematol. 1989; 72: 57–63
   PubMed Web of Science ®Google Scholar
• Martin P. J., Hansen J. A., Storb R., Thomas E. D. Human marrow transplantation: An immunological perspective. Adv. Immunol. 1987; 40: 379–389
   PubMed Web of Science ®Google Scholar
• Robertson M. J., Ritz J. Biology and clinical relevance of human natural killer cells. Blood 1990; 76: 2421–2438
   PubMed Web of Science ®Google Scholar
• Hercend T., Takvorian T., Nowill A., Tantravahi R., Moingeon P., Anderson K. C., Murray C., Bohuon C., Ythier A., Ritz J. Characterization of natural killer cells with antileukemia activity following allogeneic bone marrow transplantation. Blood 1986; 67: 722–728
   PubMed Web of Science ®Google Scholar
• Lotzova E. Role of interleukin‐2 activated MHC‐non restricted lymphocytes in antileukemia activity and therapy. Leukemia and Lymphoma 1992; 7: 15–28
   PubMed Web of Science ®Google Scholar
• Foa R., Guarini A., Tos A. G., Cardona S., Fierro M. T., Meloni G., Tosti S., Mandelli F., Gavosto F. Peripheral Blood and Bone Marrow immunophenotypic and functional modifications induced in acute leukemia patients treated with interleukin 2 evidence of in vivo lymphokine activated killer cell generation. Cancer Research 1991; 51: 964–968
   PubMed Web of Science ®Google Scholar
• Rosenberg A., Lotze M. T., Muul L. M., Chang A. E., Avis F. P., Leitman S., Linehan W. M., Robertson C. N., Lee R. E., Rubin J. T., Seipp C. A., Simpson C. G., White D. E. A progress report on the treatment of 157 patients with advanced cancer using lymphokine‐activated killer cells and interleukin‐2 or high dose interleukin‐2 alone. N. Engl. J. Med. 1987; 316: 889–897
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C., Maraninchi D., Pico J. L., Milpied N., Coiffier B., Divine M., Tiberghien P., Bosly A., Tilly H., Boulat O., Brandely M. Interleukin‐2 treatment in lymphoma: a phase II multicenter study. Blood 1994; 83: 2081–2085
   PubMed Web of Science ®Google Scholar
• Blaise D., Viens P., Olive D., Stoppa A. M., Gabert J., Pourreau C. N., Attal M., Gaspard M. H., Mannoni P., Jasmin C., Palmer P., Franks C., Michel G., Mawas C., Baume D., Philip T., Maraninchi D. Recombinant interleukin‐2 after autologous bone marrow transplantation: a pilot study in 19 patients. Eur. Cytokine Net. 1991; 2: 121–129
   PubMedGoogle Scholar
• Benyunes M. C., Massumoto C., York A., Higuchi C. M., Buckner C. D., Thompson J. A., Petersen F. B., Fefer A. Interleukin‐2 with or without lymphokine‐activated killer cells as consolidative immunotherapy after autologous bone marrow transplantation for acute myelogenous leukemia. Bone Marrow Transplantation 1993; 12: 159–163
   PubMed Web of Science ®Google Scholar
• Gottlieb D. J., Prentice H. G., Heslop H. E. Effects of recombinant interleukine‐2 administration on cyto‐toxic function following high‐dose chemo‐radiotherapy for hematological malignancy. Blood 1989; 74: 2335–2342
   PubMed Web of Science ®Google Scholar
• Hamon M. D., Prentice H. G., Gottlieb D. J., Gottlieb D. J., Macdonald I. D., Cunningham J. M., Smith O. P., Gilmore M., Gandhi L., Collis C. Preliminary report. Immunotherapy with interleukin 2 after ABMT in AML. Bone Marrow Transplantation 1993; 11: 399–401
   PubMed Web of Science ®Google Scholar
• Bosly A., Guillaume T., Brice P., Humblet Y., Staquet P., Doyen C., Chatelain B., Franks C. R., Gisselbrecht C., Symann M. Effects of escalading doses of recombinant human interleukin‐2 in correcting functional T‐cell defects following autologous bone marrow transplantation for lymphomas and solid tumors. Exp. Hematol. 1992; 20: 962–968
   PubMed Web of Science ®Google Scholar
• Costello R., Blaise D., Jacquemier J., Monges G., Stoppa A. M., Viens P., Olive D., Bouabdallah R., Brandely M., Gastaut J. A., Maraninchi D. Induction of cutaneous graft versus host like reaction by recombinant IL‐2 after autologous bone marrow transplantation. Bone Marrow Transplantation 1995; 16: 199–200
   PubMed Web of Science ®Google Scholar
• Gaspari A. A., Lotze M. T., Rosenberg S. A., Stem J. B., Katz S. I. Dermatologic changes associated with interleukin 2 administration. J. Am. Med. Assoc. 1987; 258: 1624–1629
   PubMed Web of Science ®Google Scholar
• Ettinghausen S. E., Moore J. G., White D. E., Platanias L., Young N. S., Rosenberg S. A. Hematologic effects of immunotherapy with lymphokine‐activated killer cells and recombinant IL2 in cancer patients. Blood 1987; 6: 1654–1660
   Google Scholar
• Schwartentruber D. J., White de Zweig M. H., Weintraub B. D., Rosenberg S. A. Thyroid dysfunction associated with immunotherapy for patients with cancer. Cancer 1991; 68: 2384–2390
   PubMed Web of Science ®Google Scholar
• Vialettes B., Guillerand M. A., Viens P., Stoppa A. M., Baume D., Sauvan R., Pasquier J., San Marco M., Olive D., Maraninchi D. Incidence rate risk and risk factors for thyroid dysfunction during recombinant interleukin‐2 therapy in advanced malignancies. Acta Endocrinol. 1993; 129: 31–38
   PubMedGoogle Scholar
• Murphy P. M., Lane H. C., Gallin J. I., Fauci A. S. Marked disparity in incidence of bacterial infections in patients with the acquired immunodeficiency syndrome receiving interleukin‐2 or interferon gamma. Ann. Intern. Med. 1988; 108: 36–41
   PubMed Web of Science ®Google Scholar
• Blaise D., Stoppa A. M., Viens P., Sainty D., Fossat C., Miquel M., Olive D., Bouabdallah R., Gabert J., Baume D., Maraninchi D. Intensive immunotherapy with recombinant 1L2 after autologous bone marrow transplantation is associated with a high incidence of bacterial infections. Bone Marrow Transplantation 1992; 10: 193–195
   PubMed Web of Science ®Google Scholar
• Attal M., Blaise D., Marit G., Payen C., Michallet M., Vernant J. P., Sauvage C., Troussard X., Nedellec G., Pico J. L., Huguet F., Stoppa A. M., Broustet A., Sotto J. J., Pris J., Maraninchi D., Reiffers J. Consolidation treatment of adult acute lymphoblastic leukemia a prospective, randomized trial comparing allogeneic versus autologous bone marrow transplantation and testing the impact of recombinant Interleukin‐2 after autologous bone marrow transplantation. Blood 1980; 86(4)1619–1628
   Google Scholar
• Blaise D., Olive D., Stoppa A. M., Viens P., Pourreau C., Lopez M., Attal M., Jasmin C., Monges G., Mawas C., Mannoni P., Palmer P., Franks C., Philip T., Maraninchi D. Hematologic and Immunologic effects of the systemic administration of recombinant interleukin‐2 after autologous bone marrow transplantation. Blood 1990; 76: 1092–1097
   PubMed Web of Science ®Google Scholar
• Sykes M., Abraham V. S., Harty N. W., Pearson D. A. IL2 reduces graft versus host disease and preserves a graft versus leukemia effect by selectively inhibiting CD4+ T cell activity. J. Immunol. 1993; 150: 197–205
   PubMed Web of Science ®Google Scholar
• Smith K. A. Lowest dose interleukin‐2 immunotherapy. Blood, 81: 1414–1423
   PubMed Web of Science ®Google Scholar
• Atzpodien J., Körfer A., Franks C. R., Poliwoda H., Kirchner H. Home therapy with recombinant interleukin‐2 and interferon α2b in advanced human malignancies. Lancet 1990; 335: 1509–1512
   PubMed Web of Science ®Google Scholar
• Soiffer R. J., Murray C., Gonin R., Ritz J. Effect of low dose interleukin‐2 on disease relapse after T‐cell depleted allogeneic bone marrow transplantation. Blood 1994; 84: 964–971
   PubMed Web of Science ®Google Scholar
• Weisdorf D. J., Anderson P. M., Blazar B. R., Uckun F. M., Kersey J. H., Ramsay N. K. Interleukin‐2 immediately after autologous bone marrow transplantation for acute lymphoblastic leukemia: a phase I study. Transplantation 1993; 55: 61–66
   PubMed Web of Science ®Google Scholar
• Brenner M. K., Heslop H. E. Immunotherapy of leukemia. Leukemia 1992; 6: 76–79
   PubMed Web of Science ®Google Scholar
• Lehmann F., Marchand M., Hainaut P., Pouillart P., Sastre X., Ikeda H., Boon T., Coulie P. G. Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection. Eur. J. Immunol. 1995; 25: 340
   PubMed Web of Science ®Google Scholar
• Foa R. Does interleukin‐2 have a role in the management of acute leukemia. J. Clin. Oncol. 1993; 11: 1817–1825
   PubMed Web of Science ®Google Scholar
• Maraninchi D., Blaise D., Viens P., Brandely M., Olive D., Lopez M., Sainty D., Marit G., Stoppa A. M., Reiffers J., Gratecos N., Bertau‐Perez P., Mannoni P., Mawas C., Hercend T., Sebahoun G., Carcassonne Y. High dose recombinant interleukin‐2 and acute myeloid leukemias in relapse. Blood 1991; 78: 2182–2187
   PubMed Web of Science ®Google Scholar
• Meloni G., Foa R., Vignetti M., Guarini A., Fenu S., Tosti A. G., Mandelli F. Interleukin‐2 may induce prolonged remissions in advanced acute myelogenous leukemia. Blood 1994; 84: 2158–2163
   PubMed Web of Science ®Google Scholar
• Reittie J. E., Gottlieb D., Heslop H. E., Leger O., Drexler H. G., Hazlehurst G., Hoffbrand A. V., Prentice H. G., Brenner M. K. Endogenously generated activated killer cells circulate after autologous and allogeneic marrow transplantation but not after chemotherapy. Blood 1989; 73: 1351–1358
   PubMed Web of Science ®Google Scholar
• Higuchi C. M., Thompson J. A., Cox T., Lindgren C. G., Buckner C. D., Fefer A. Lymphokine activated killer function following autologous bone marrow transplantation for refractory hematological malignancies. Cancer Research 1989; 49: 5509–5513
   PubMed Web of Science ®Google Scholar
• Fierro M. T., Liao X. S., Lusso P., Bonferroni M., Matera L., Cesano A., Lista P., Arione R., Forni G., Foa R. In vitro and in vivo susceptibility of human leukemic cells to lymphokine activated killer activity. Leukemia 1988; 2: 50–54
   PubMed Web of Science ®Google Scholar
• Brenner M. K., Rill D. R., Moen R. C., Krance C., Miro J., Anderson W. F., Ihle J. N. Gene marking to trace origin of relapse after autologous bone marrow transplantation. Lancet 1993; 341: 85–86
   PubMed Web of Science ®Google Scholar
• Fefer A., Einstein A. B., Thomas D., Buckner C. D., Clift R. A., Glucksberg H., Neiman P. E., Storb R. Bone marrow transplantation for hematologic neoplasia in 16 patients with identical twins. The New Engl. J. of Med., 290: 1389–1393
   PubMed Web of Science ®Google Scholar